Breaking News Instant updates and real-time market news.

ITCI

Intra-Cellular

$11.99

-0.18 (-1.48%)

14:25
04/18/19
04/18
14:25
04/18/19
14:25

Intra Cellular Therapies call volume above normal and directionally bullish

Bullish option flow detected in Intra Cellular Therapies with 1,795 calls trading, 1.3x expected, and implied vol increasing over 21 points to 203.10%. May-19 17.5 calls and Apr-19 12.5 puts are the most active options, with total volume in those strikes near 1,700 contracts. The Put/Call Ratio is 0.29. Earnings are expected on May 2nd.

  • 27

    Sep

ITCI Intra-Cellular
$11.99

-0.18 (-1.48%)

08/23/18
CANT
08/23/18
NO CHANGE
Target $32
CANT
Overweight
Intra-Cellular transferred with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan took over coverage of Intra-Cellular Therapies with an Overweight rating and $32 price target. The analyst sees a high probability of approval for lumateperone in schizophrenia.
11/13/18
LEER
11/13/18
INITIATION
Target $27
LEER
Outperform
Intra-Cellular initiated with an Outperform at Leerink
Leerink analyst Marc Goodman started Intra-Cellular with an Outperform and $27 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Intra-Cellular, Goodman believes that lumateperone should get approved for the treatment of schizophrenia and drive about $400M of peak sales for this indication in 2029.
12/12/18
ADAM
12/12/18
NO CHANGE
Target $31
ADAM
Buy
Intra-Cellular's NDA acceptance puts some investors fears to bed, says Canaccord
Canaccord analyst Sumant Kulkarni maintained a Buy rating and $31 price target on Intra-Cellular after the FDA accepted its new drug application for lumateperone for schizophrenia, and granted a PDUFA date of September 27, 2019, which paves the way for the company to potentially have a product on the market next year. In a research note to investors, Kulkarni says the NDA acceptance was expected, but the announcement puts some investor fears to bed. If approved, the analyst believes lumateperone could present a meaningful product for the treatment of schizophrenia given its relatively benign safety/side effect profile vs. the current standard of care.
12/12/18
12/12/18
NO CHANGE
Target $37

Outperform
Intra-Cellular price target raised to $37 from $35 at RBC Capital
As previously reported, RBC Capital analyst Brian Abrahams raised Intra-Cellular's price target to $37 from $35, saying the FDA NDA acceptance "meaningfully" de-risked the potential for lead drug lumateperone in its most advanced indication, schizophrenia. The analyst also believe shares significantly undervalue lumateperone's potential across neuropsych indications, with potential for bipolar depression data and schizophrenia approval to catalyze upside in 2019. He keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

HUYA

Huya

$18.21

0.6 (3.41%)

05:35
12/12/19
12/12
05:35
12/12/19
05:35
Initiation
Huya initiated  »

Huya initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMAB

Genmab

, AZN

AstraZeneca

$48.19

0.23 (0.48%)

05:32
12/12/19
12/12
05:32
12/12/19
05:32
Downgrade
Genmab, AstraZeneca, Roche rating change  »

Genmab downgraded to Hold…

GMAB

Genmab

AZN

AstraZeneca

$48.19

0.23 (0.48%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 16

    Dec

  • 17

    Dec

WBA

Walgreens Boots Alliance

$58.00

-0.4 (-0.68%)

, MCK

McKesson

$143.40

0.59 (0.41%)

05:31
12/12/19
12/12
05:31
12/12/19
05:31
Hot Stocks
Walgreens Boots Alliance, McKesson create German wholesale JV »

Walgreens Boots Alliance…

WBA

Walgreens Boots Alliance

$58.00

-0.4 (-0.68%)

MCK

McKesson

$143.40

0.59 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

MTUAY

MTU Aero Engines

$0.00

(0.00%)

05:30
12/12/19
12/12
05:30
12/12/19
05:30
Downgrade
MTU Aero Engines rating change  »

MTU Aero Engines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

, HALO

Halozyme

$18.74

-0.46 (-2.40%)

05:30
12/12/19
12/12
05:30
12/12/19
05:30
Hot Stocks
Genentech says Phase III FeDeriCa study met primary endpoint »

Genentech, a member of…

RHHBY

Roche

$0.00

(0.00%)

HALO

Halozyme

$18.74

-0.46 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 16

    Dec

OEZVY

Verbund

$0.00

(0.00%)

05:28
12/12/19
12/12
05:28
12/12/19
05:28
Upgrade
Verbund rating change  »

Verbund upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALV

Autoliv

$83.17

0.81 (0.98%)

05:25
12/12/19
12/12
05:25
12/12/19
05:25
Upgrade
Autoliv rating change  »

Autoliv upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

AMGN

Amgen

$233.96

0.14 (0.06%)

05:25
12/12/19
12/12
05:25
12/12/19
05:25
Hot Stocks
Amgen, UCB announce EC approval of EVENITY »

Amgen and UCB announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KR

Kroger

$28.03

0.14 (0.50%)

05:25
12/12/19
12/12
05:25
12/12/19
05:25
Upgrade
Kroger rating change  »

Kroger upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMWYY

BMW

$0.00

(0.00%)

05:23
12/12/19
12/12
05:23
12/12/19
05:23
Upgrade
BMW rating change  »

BMW upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$49.60

0.43 (0.87%)

05:23
12/12/19
12/12
05:23
12/12/19
05:23
Upgrade
Charles Schwab rating change  »

Charles Schwab upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVKIF

Evonik

$0.00

(0.00%)

05:22
12/12/19
12/12
05:22
12/12/19
05:22
Upgrade
Evonik rating change  »

Evonik upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SOLVY

Solvay

$0.00

(0.00%)

05:22
12/12/19
12/12
05:22
12/12/19
05:22
Downgrade
Solvay rating change  »

Solvay downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SOLVY

Solvay

$0.00

(0.00%)

05:21
12/12/19
12/12
05:21
12/12/19
05:21
Upgrade
Solvay rating change  »

Solvay upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$86.59

0.56 (0.65%)

05:19
12/12/19
12/12
05:19
12/12/19
05:19
Upgrade
Starbucks rating change  »

Starbucks upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWI

SolarWinds

$18.28

0.1 (0.55%)

05:19
12/12/19
12/12
05:19
12/12/19
05:19
Recommendations
SolarWinds analyst commentary  »

SolarWinds remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAKE

Cheesecake Factory

$40.73

-0.77 (-1.86%)

05:14
12/12/19
12/12
05:14
12/12/19
05:14
Initiation
Cheesecake Factory initiated  »

Cheesecake Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXRH

Texas Roadhouse

$57.25

0.55 (0.97%)

05:13
12/12/19
12/12
05:13
12/12/19
05:13
Initiation
Texas Roadhouse initiated  »

Texas Roadhouse initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

DRI

Darden

$117.44

-1.15 (-0.97%)

05:11
12/12/19
12/12
05:11
12/12/19
05:11
Initiation
Darden initiated  »

Darden initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

EAT

Brinker

$41.12

-0.225 (-0.54%)

05:09
12/12/19
12/12
05:09
12/12/19
05:09
Initiation
Brinker initiated  »

Brinker initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLMN

Bloomin' Brands

$21.95

-0.065 (-0.30%)

05:08
12/12/19
12/12
05:08
12/12/19
05:08
Initiation
Bloomin' Brands initiated  »

Bloomin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$9.62

0.62 (6.89%)

05:05
12/12/19
12/12
05:05
12/12/19
05:05
Downgrade
Bright Scholar rating change  »

Bright Scholar downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$88.09

0.165 (0.19%)

04:59
12/12/19
12/12
04:59
12/12/19
04:59
Recommendations
Wayfair analyst commentary  »

Wayfair price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

MD

Mednax

$26.75

1.975 (7.97%)

04:56
12/12/19
12/12
04:56
12/12/19
04:56
Upgrade
Mednax rating change  »

Mednax upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNFT

Genfit

$15.38

-0.805 (-4.97%)

04:55
12/12/19
12/12
04:55
12/12/19
04:55
Conference/Events
Roth Capital healthcare analyst to hold an analyst/industry conference call »

Healthcare Analyst Rahimi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 18

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.